Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

Table 7 K-MMSE and other test scores at baseline and the 12th and 24th week

Variables	KGT group (n = 16)				Placebo group (n = 14)				Between-group comparison
Variables	Baseline	12th week	24th week	p-value^§	Baseline	12th week	24th week	p-value^§	p-value^*
K-MMSE score	28.5 (26.3–29.0)	28.5 (27.0–30.0)	28.0 (26.3–29.8)	0.168	26.0 (24.8–28.3)	26.5 (24.5–28.0)	27.5 (25.0–28.0)	0.667	0.097
GDS
2	0 (0%)		5 (31.25%)	–	0 (0%)		2 (14.29%)	–	0.399
3	16 (100%)		11 (68.75%)	–	14 (100%)		12 (85.71%)	–	0.399
Barthel-ADL	20		20	–	20		20	–	–
K-IADL	1.0 (1.0–2.0)		1.0 (1.0–1.0)	0.438	1.0 (1.0–1.3)		1.0 (1.0–2.0)	1.000	0.994
SGDS	4.0 (1.3–10.8)		2.0 (1.0–8.5)	0.063	2.5 (1.8–9.0)		4.5 (1.0–8.3)	0.591	0.464

K-MMSE, Korean Mini Mental State Examination; KGT, Kami-guibi-tang; GDS, Global Deterioration Scale; SGDS, Short version-Geriatric Depression Scale; K-IADL, Korean-Instrumental Activities of Daily Living; Barthel-ADL, Barthel-Activities of Daily Living
Data are presented as medians (Q1–Q3) or numbers (%)
^§p-value for the intergroup comparison using the Friedman test
^*p-value for the between-group comparison using the Mann-Whitney U test or Pearson’s chi-square test

ISSN: 2662-7671